The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | Therapeutic agents being explored in Waldenström’s macroglobulinemia trials
Shirley D’Sa, MD, FRCP, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, briefly summarizes novel agents being explored in clinical trials for the treatment of Waldenström’s macroglobulinemia (WM), commenting on the promise of zanubrutinib, based on findings from the ASPEN trial (NCT03053440). Dr D’Sa also outlines the promise of the CLOVER-WaM study, which will assess the use of CLR 131 in patients with WM. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen- speaker fees, research grants, congress support, advisory boards
BeiGene- speaker fees, research grants, congress support, advisory boards
Sanofi- speaker fees, advisory boards
